LGND

Nasdaq

LIGAND PHARMACEUTICALS INC

Latest disclosureOctober 6, 2026

Insider score Why 0?: 0/ 100
Qualifying buys · 30d: $0

0 purchases · 74 sales

Price by TradingView

Insider transactions 139

Limited filing history

Filters

Last 30 daysNo qualifying insider buying. Sales: $3.29M by 2 insiders.

Showing the first 6 of 20 trades on this page.

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $251.99K
Reported price: $302.5107 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $599.8K
Reported price: $303.5444 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $467.43K
Reported price: $304.5154 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $123.7K
Reported price: $306.1834 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $72.19K
Reported price: $307.1911 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $5.23K
Reported price: $307.74 / share

Sale disclosed

Martine Zimmermann

Director

Common Stock

Reported value: $342K
Reported price: $285.00 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $85.2K
Reported price: $283.9854 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $513.3K
Reported price: $285.1671 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $605.65K
Reported price: $286.3589 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $110.7K
Reported price: $287.5253 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $115.59K
Reported price: $288.9792 / share

Sale disclosed

Octavio Espinoza

Chief Financial Officer

Common Stock

Reported value: $9.24M
Reported price: $292.065 / share

Sale disclosed

Jason Haas

Director

Common Stock

Reported value: $2.09M
Reported price: $292.8078 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $29.83K
Reported price: $284.1375 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $9.39K
Reported price: $284.553 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $44.86K
Reported price: $285.7357 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $295.97K
Reported price: $286.7968 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $349.36K
Reported price: $287.7731 / share

Sale disclosed

Andrew Reardon

CLO & Secretary

Common Stock

Reported value: $102.79K
Reported price: $288.7496 / share

Reporting insider	Security / transaction	Amount / price	Value	Traded / disclosed	Source
CLO & Secretary	Common StockSale10b5-16 trades	5,000avg $304.07 / share	$1.52M	Oct 2Filed Oct 6 · 4d later	6 filings 833 @ $302.51 · $251.99KSEC filing 1,976 @ $303.54 · $599.8KSEC filing 1,535 @ $304.52 · $467.43KSEC filing 404 @ $306.18 · $123.7KSEC filing 235 @ $307.19 · $72.19KSEC filing 17 @ $307.74 · $5.23KSEC filing
Director	Common StockSale	1,200$285.00 / share	$342K	Sep 10Filed Sep 14 · 4d later	SEC filing
CLO & Secretary	Common StockSale10b5-15 trades	5,000avg $286.09 / share	$1.43M	Sep 3Filed Sep 8 · 5d later	5 filings 300 @ $283.99 · $85.2KSEC filing 1,800 @ $285.17 · $513.3KSEC filing 2,115 @ $286.36 · $605.65KSEC filing 385 @ $287.53 · $110.7KSEC filing 400 @ $288.98 · $115.59KSEC filing
Chief Financial Officer	Common StockSale10b5-1	31,641$292.07 / share	$9.24M	Aug 12Filed Aug 14 · 2d later	SEC filing
Director	Common StockSale	7,138$292.81 / share	$2.09M	Aug 12Filed Aug 14 · 2d later	SEC filing
CLO & Secretary	Common StockSale10b5-16 trades	2,897avg $287.27 / share	$832.21K	Aug 3Filed Aug 4 · 1d later	6 filings 105 @ $284.14 · $29.83KSEC filing 33 @ $284.55 · $9.39KSEC filing 157 @ $285.74 · $44.86KSEC filing 1,032 @ $286.80 · $295.97KSEC filing 1,214 @ $287.77 · $349.36KSEC filing 356 @ $288.75 · $102.79KSEC filing

Showing the latest 20 of 74 trades. Show all 74 trades

Congress transactions 4

All Congress filings

Purchase disclosed

Ligand Pharmaceuticals Incorporated - Common Stock (LGND) · Stock

The filing reports a purchase for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: May 29, 2026

Purchase disclosed

Ligand Pharmaceuticals Incorporated - Common Stock (LGND) · Stock

The filing reports a purchase for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 3, 2026

Purchase disclosed

Ligand Pharmaceuticals Incorporated - Common Stock (LGND) · Stock

The filing reports a purchase for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: January 15, 2026

Purchase disclosed

Ligand Pharmaceuticals Incorporated - Common Stock (LGND) · Stock

The filing reports a purchase for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: January 5, 2026

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0000886163
Latest public acceptance: Oct 6, 2026, 08:35 PM UTC
Score calculated: Oct 8, 2026, 12:04 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.

Reporting insider

Security / transaction

Amount / price

Value

Traded / disclosed

Source

CLO & Secretary

Common StockSale10b5-16 trades

5,000avg $304.07 / share

$1.52M

Oct 2Filed Oct 6 · 4d later

6 filings

833 @ $302.51 · $251.99KSEC filing
1,976 @ $303.54 · $599.8KSEC filing
1,535 @ $304.52 · $467.43KSEC filing
404 @ $306.18 · $123.7KSEC filing
235 @ $307.19 · $72.19KSEC filing
17 @ $307.74 · $5.23KSEC filing

Director

Common StockSale

1,200$285.00 / share

$342K

Sep 10Filed Sep 14 · 4d later

SEC filing

CLO & Secretary

Common StockSale10b5-15 trades

5,000avg $286.09 / share

$1.43M

Sep 3Filed Sep 8 · 5d later

5 filings

300 @ $283.99 · $85.2KSEC filing
1,800 @ $285.17 · $513.3KSEC filing
2,115 @ $286.36 · $605.65KSEC filing
385 @ $287.53 · $110.7KSEC filing
400 @ $288.98 · $115.59KSEC filing

Chief Financial Officer

Common StockSale10b5-1

31,641$292.07 / share

$9.24M

Aug 12Filed Aug 14 · 2d later

SEC filing

Director

Common StockSale

7,138$292.81 / share

$2.09M

Aug 12Filed Aug 14 · 2d later

SEC filing

CLO & Secretary

Common StockSale10b5-16 trades

2,897avg $287.27 / share

$832.21K

Aug 3Filed Aug 4 · 1d later

6 filings

105 @ $284.14 · $29.83KSEC filing
33 @ $284.55 · $9.39KSEC filing
157 @ $285.74 · $44.86KSEC filing
1,032 @ $286.80 · $295.97KSEC filing
1,214 @ $287.77 · $349.36KSEC filing
356 @ $288.75 · $102.79KSEC filing

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0000886163
Latest public acceptance: Oct 6, 2026, 08:35 PM UTC
Score calculated: Oct 8, 2026, 12:04 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.